Literature DB >> 34647463

Reactivities of the Front Pocket N-Terminal Cap Cysteines in Human Kinases.

Ruibin Liu1, Shaoqi Zhan1, Ye Che2, Jana Shen1.   

Abstract

The front pocket (FP) N-terminal cap (Ncap) cysteine is the most popular site of covalent modification in kinases. A long-standing hypothesis associates the Ncap position with cysteine hyper-reactivity; however, traditional computational predictions suggest that the FP Ncap cysteines are predominantly unreactive. Here we applied the state-of-the-art continuous constant pH molecular dynamics (CpHMD) to test the Ncap hypothesis. Simulations found that the Ncap cysteines of BTK/BMX/TEC/ITK/TXK, JAK3, and MKK7 are reactive to varying degrees; however, those of BLK and EGFR/ERBB2/ERBB4 possessing a Ncap+3 aspartate are unreactive. Analysis suggested that hydrogen bonding and electrostatic interactions drive the reactivity, and their absence renders the Ncap cysteine unreactive. To further test the Ncap hypothesis, we examined the FP Ncap+2 cysteines in JNK1/JNK2/JNK3 and CASK. Our work offers a systematic understanding of the cysteine structure-reactivity relationship and illustrates the use of CpHMD to differentiate cysteines toward the design of targeted covalent inhibitors with reduced chemical reactivities.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34647463      PMCID: PMC8812259          DOI: 10.1021/acs.jmedchem.1c01186

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  81 in total

1.  Evolution of CASK into a Mg2+-sensitive kinase.

Authors:  Konark Mukherjee; Manu Sharma; Reinhard Jahn; Markus C Wahl; Thomas C Südhof
Journal:  Sci Signal       Date:  2010-04-27       Impact factor: 8.192

2.  Olmutinib: First Global Approval.

Authors:  Esther S Kim
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

Review 3.  Orelabrutinib: First Approval.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2021-03-11       Impact factor: 9.546

Review 4.  Kinase inhibitors: the road ahead.

Authors:  Fleur M Ferguson; Nathanael S Gray
Journal:  Nat Rev Drug Discov       Date:  2018-03-16       Impact factor: 84.694

Review 5.  Progress with covalent small-molecule kinase inhibitors.

Authors:  Zheng Zhao; Philip E Bourne
Journal:  Drug Discov Today       Date:  2018-01-11       Impact factor: 7.851

6.  Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation.

Authors:  Alan K Kutach; Armando G Villaseñor; Diana Lam; Charles Belunis; Cheryl Janson; Stephen Lok; Li-Na Hong; Chao-Min Liu; Jerome Deval; Thomas J Novak; Jim W Barnett; Wei Chu; David Shaw; Andreas Kuglstatter
Journal:  Chem Biol Drug Des       Date:  2010-06-09       Impact factor: 2.817

7.  Characterization of Covalent Pyrazolopyrimidine-MKK7 Complexes and a Report on a Unique DFG-in/Leu-in Conformation of Mitogen-Activated Protein Kinase Kinase 7 (MKK7).

Authors:  Patrik Wolle; Julian Engel; Steven Smith; Lisa Goebel; Elisabeth Hennes; Jonas Lategahn; Daniel Rauh
Journal:  J Med Chem       Date:  2019-05-31       Impact factor: 7.446

8.  The catalytic site of glutathione peroxidases.

Authors:  Silvio C E Tosatto; Valentina Bosello; Federico Fogolari; Pierluigi Mauri; Antonella Roveri; Stefano Toppo; Leopold Flohé; Fulvio Ursini; Matilde Maiorino
Journal:  Antioxid Redox Signal       Date:  2008-09       Impact factor: 8.401

Review 9.  JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.

Authors:  George E Fragoulis; Iain B McInnes; Stefan Siebert
Journal:  Rheumatology (Oxford)       Date:  2019-02-01       Impact factor: 7.580

10.  Assessment of proton-coupled conformational dynamics of SARS and MERS coronavirus papain-like proteases: Implication for designing broad-spectrum antiviral inhibitors.

Authors:  Jack A Henderson; Neha Verma; Robert C Harris; Ruibin Liu; Jana Shen
Journal:  J Chem Phys       Date:  2020-09-21       Impact factor: 3.488

View more
  2 in total

1.  Profiling MAP kinase cysteines for targeted covalent inhibitor design.

Authors:  Ruibin Liu; Neha Verma; Jack A Henderson; Shaoqi Zhan; Jana Shen
Journal:  RSC Med Chem       Date:  2021-11-03

2.  Proteome-Wide Profiling of the Covalent-Druggable Cysteines with a Structure-Based Deep Graph Learning Network.

Authors:  Hongyan Du; Dejun Jiang; Junbo Gao; Xujun Zhang; Lingxiao Jiang; Yundian Zeng; Zhenxing Wu; Chao Shen; Lei Xu; Dongsheng Cao; Tingjun Hou; Peichen Pan
Journal:  Research (Wash D C)       Date:  2022-07-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.